Use profile and costs of carbapenemics in an intensive care unit in Distrito Federal – Brazil
DOI:
https://doi.org/10.33448/rsd-v10i14.21691Keywords:
Pharmacoepidemiology; Antimicrobial stewardship; Hospital care.Abstract
Currently, the context of microbial resistance has required management of the use of antimicrobials, especially in the hospital environment. Thus, the aim of this study was to analyze the profile of carbapenems use in the Intensive Care Unit (ICU) of a Brazilian public hospital and the associated costs. To this end, a retrospective observational study of document analysis was carried out, which evaluated medical records, prescriptions and microbiological reports of patients who used carbapenems in 2019. Data from 25 patients with a median age of 65 years and length of hospital stay were 24 days. There were 36 analyzes of the use of carbapenems: 19 (57.8%) referred to the use of meropenem and 17 (47.2%) to the use of ertapenem. The median number of days of use of meropenem was 11 and that of ertapenem was seven. The DDD/1000 patient-days of meropenem had a monthly median of 115.5g (lower when used with ertapenem) and that of ertapenem was 50.7g. The total annual expenditure was R$16,652.00 for meropenem and R$41,072.00 for ertapenem. Sixty microbiological reports were carried out and the most frequent microorganisms were Klebsiella pneumoniae (n=18; 30.0%) and Acinetobacter baumannii complex/haemolyticus (n=14; 23.3%); the overall sensitivity rate was 18.3% for meropenem and 13.6% for ertapenem. The data suggest the need to manage the use of carbapenems considering aspects of the patient and the infectious agent with a potential positive impact on clinical and economic outcomes. For this, proposals for the rational and safe use of antimicrobials must be implemented, emphasizing the importance of each professional in the context of the multidisciplinary team.
References
Abdallah, M., Badawi, M., Alzaagi, I., Issa, K. N., Rasheed, A., & Alharthy, A. (2019). Effect of short-term carbapenem restriction on the incidence of non-pseudomonal multi-drug resistant Gram-negative bacilli in an intensive care unit. Journal of Chemotherapy, 31(5), 261–266. https://doi.org/10.1080/1120009X.2019.1601802
Abdul-Aziz, M. H., Alffenaar, J. W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J. A., Pea, F., Sjovall, F., Timsit, J. F., Udy, A. A., Wicha, S. G., Zeitlinger, M., De Waele, J. J., & Roberts, J. A. (2020). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Medicine, 46(6), 1127–1153. https://doi.org/10.1007/s00134-020-06050-1
Alp, E., & Damani, N. (2015). Review Healthcare-associated infections in Intensive Care Units: epidemiology and infection control in low-to-middle income countries. The Journal of Infection in Developing Countries, 9(10), 1040–1045. https://doi.org/10.3855/jidc.6832
Alyahawi, A., Alrubaiee, G., & Alkaf, A. (2020). Evaluation of Carbapenem Use Among Patients At Intensive Care Unit (Icu) in Sana’a, Yemen. Universal Journal of Pharmaceutical Research, 4(6), 30–34. https://doi.org/10.22270/ujpr.v4i6.333
Araujo, T. G. de, Rieder, M. de M., Kutchak, F. M., & Franco Filho, J. W. (2013). Readmissões e óbitos após a alta da UTI - um desafio da terapia intensiva. Revista Brasileira de Terapia Intensiva Intensiva, 25(1), 32–38.
Balkhy, H. H., El-Saed, A., El-Metwally, A., Arabi, Y. M., Aljohany, S. M., Al Zaibag, M., Baharoon, S., & Alothman, A. F. (2018). Antimicrobial consumption in five adult intensive care units: A 33-month surveillance study. Antimicrobial Resistance and Infection Control, 7(1), 1–9. https://doi.org/10.1186/s13756-018-0451-9
Baroni, F. C. de S., Ferreira, M. M., & Roese, F. M. (2017). Perfil de utilização de antimicrobianos na unidade de terapia intensiva de um hospital público. Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde, 8(4), 37–44. https://doi.org/10.30968/rbfhss.2017.084.007
Brasil. (2017). Diretriz Nacional para Elaboração de Programa de Gerenciamento do Uso de Antimicrobianos em Serviços de Saúde - Agência Nacional de Vigilância Sanitária. https://www20.anvisa.gov.br/segurancadopaciente/index.php/publicacoes/item/diretriz-nacional-para-elaboracao-de-programa-de-gerenciamento-do-uso-de-antimicrobianos-em-servicos-de-saude
Carvalho, P. P., Porto, M. de J., Barros, J. F., Magalhães, A. S., Nunes, L. S., Silva, I. C., Abreu, I. L. S. de, Souza, G. N., Neto, J. M. de R., & Mendes, T. da S. (2021). Avaliação de pacientes críticos com suspeita de sepse em um hospital universitário. Research, Society and Development, 10(3), 1–12. https://doi.org/http://dx.doi.org/10.33448/rsd-v10i3.13570
Chatzopoulou, M., & Reynolds, L. (2020). Role of antimicrobial restrictions in bacterial resistance control: a systematic literature review. Journal of Hospital Infection, 104(2), 125–136. https://doi.org/10.1016/j.jhin.2019.09.011
Codjoe, F. S., & Donkor, E. S. (2018). Carbapenem Resistance : A Review. Medical Sciences, 6(1), 1–28. https://doi.org/10.3390/medsci6010001
Coêlho, T. da S., Oliveira, R. A., Lúcio Neto, M. P., Santos, P. N., & Silva, G. de A. (2020). Análise do consumo de antimicrobianos em pacientes críticos de um hospital de referência no Piauí. Research, Society and Development, 9(7), 1–15.
Furtado, D. M. F., Silveira, V. S. da, Carneiro, I. C. do R. S., Furtado, D. M. F., & Kilishek, M. P. (2019). Consumo de antimicrobianos e o impacto na resistência bacteriana em um hospital público do estado do Pará, Brasil, de 2012 a 2016. Revista Pan-Amazônica de Saúde, 10(0), 1–8. https://doi.org/10.5123/s2176-6223201900041
Gajdács, M. (2019). The Concept of an Ideal Antibiotic: Implications for Drug Design. Molecules, 24, 1–16. https://doi.org/10.3390/molecules24050892
Joseph, N. M., Bhanupriya, B., Shewade, D. G., & Harish, B. N. (2015). Relationship between antimicrobial consumption and the incidence of antimicrobial resistance in Escherichia coli and Klebsiella pneumoniae isolates. Journal of Clinical and Diagnostic Research, 9(2), DC08-DC12. https://doi.org/10.7860/JCDR/2015/11029.5537
Khan, H. A., Baig, F. K., & Mehboob, R. (2017). Nosocomial infections: Epidemiology, prevention, control and surveillance. Asian Pacific Journal of Tropical Biomedicine, 7(5), 478–482. https://doi.org/10.1016/j.apjtb.2017.01.019
Kollef, M. H., Bassetti, M., Francois, B., Burnham, J., Dimopoulos, G., Garnacho-Montero, J., Lipman, J., Luyt, C.-E., Nicolau, D. P., Postma, M. J., Torres, A., Welte, T., & Wunderink, R. G. (2017). The intensive care medicine research agenda on multidrug- resistant bacteria, antibiotics, and stewardship. Intensive Care Medicine, 43(9), 1187–1197. https://doi.org/10.1007/s00134-017-4682-7
Li, Y., Wang, J., Wang, R., & Cai, Y. (2020). Double-carbapenem therapy in the treatment of multidrug resistant Gram- negative bacterial infections : a systematic review and meta-analysis. BMC Infectious Diseases, 20, 1–13.
Lima, A. L. L. M., Oliveira, P. R. D. de, Paula, A. P. de, Dal-Paz, K., Almeida Jr, J. N. de, Félix, C. da S., & Rossi, F. (2011). Carbapenem stewardship: positive impact on hospital ecology. Brazilian Journal of Infectious Diseases, 15(1), 1–5. https://doi.org/10.1590/s1413-86702011000100001
Lobo, L. G., Ramos, F., Moretti, M. M., & Alves, P. H. (2017). Resultados de um Programa Multidisciplinar de Otimização do Uso de Antimicrobianos. Revista de Epidemiologia e Controle de Infecção, 7(1), 1–5. https://doi.org/10.17058/reci.v7i1.7279
McCann, E., Srinivasan, A., Andrew DeRyke, C., Ye, G., DePestel, D. D., Murray, J., & Gupta, V. (2018). Carbapenem-nonsusceptible Gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: A multicenter study. Open Forum Infectious Diseases, 5(10), 1–7. https://doi.org/10.1093/ofid/ofy241
Micek, S. T., Welch, E. C., Khan, J., Pervez, M., Doherty, J. A., Reichley, R. M., & Kollef, M. H. (2010). Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: A retrospective analysis. Antimicrobial Agents and Chemotherapy, 54(5), 1742–1748. https://doi.org/10.1128/AAC.01365-09
O’Neill, J. (2014). Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations.
Oliva, A., Scorzolini, L., Castaldi, D., Gizzi, F., Angelis, M. De, Storto, M., D’Abramo, A., Aloj, F., Mascellino, M. T., Mastroianni, C. M., & Vullo, V. (2017). Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem- resistant Klebsiella pneumoniae (CR-Kp). Journal of Infection, 74, 103–106. https://doi.org/10.1016/j.jinf.2016.10.002
Organização Mundial da Saúde. (2020). 2020 Antibacterial agents in clinical and preclinical development: an overview and analysis. https://www.who.int/publications/i/item/9789240021303
Organização Mundial da Saúde. (2021). WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2021. https://www.whocc.no/filearchive/publications/2021_guidelines_web.pdf
Paiva, J. A., Mergulhão, P., & Figueira Salluh, J. I. (2020). What every intensivist must know about antimicrobial stewardship: Its pitfalls and its challenges. Revista Brasileira de Terapia Intensiva, 32(2), 207–212. https://doi.org/10.5935/0103-507X.20200037
Pascale, G. De, Martucci, G., Montini, L., Panarello, G., Cutuli, S. L., Carlo, D. Di, Gravio, V. Di, Stefano, R. Di, Capitanio, G., Vallecoccia, M. S., Polidori, P., Spanu, T., Arcadipane, A., & Antonelli, M. (2017). Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections : a two-center , matched case – control study. Critical Care, 21, 1–10. https://doi.org/10.1186/s13054-017-1769-z
Patrier, J., & Timsit, J. F. (2020). Carbapenem use in critically ill patients. Current Opinion in Infectious Diseases, 33(1), 86–91. https://doi.org/10.1097/QCO.0000000000000622
Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., Waele, J. J. De, Dimopoulos, G., Kaukonen, K., Koulenti, D., Martin, C., Montravers, P., Rello, J., Rhodes, A., Starr, T., Wallis, S. C., & Lipman, J. (2014). DALI: Defining Antibiotic Levels in Intensive Antibiotic Doses Sufficient for Critically Ill Care Unit Patients: Are Current β-Lactam Patients? Clinical Infectious Diseases, 58(8), 1072–1083. https://doi.org/10.1093/cid/ciu027
Rodrigues, F. d’Athayde, & Bertoldi, A. D. (2010). Perfil da utilização de antimicrobianos em um hospital privado. Ciência & Saúde Coletiva, 15(suppl 1), 1239–1247. https://doi.org/10.1590/s1413-81232010000700033
Santos, P. N. do, Silva, G. de A., Coêlho, T. da S., Oliveira, R. A. de, & Neto, M. P. L. (2020). Análise farmacoeconômica dos antimicrobianos na unidade de terapia intensiva em um hospital terciário. Research, Society and Development, 9(5), 1–18. https://doi.org/http://dx.doi.org/10.33448/rsd-v9i5.3179
Silva, M. C. M. da, Sousa, R. M. C., & Padilha, K. G. (2011). Fatores associados ao óbito e a readmissão em Unidade de Terapia Intensiva. Revista Latino-Americana de Enfermagem, 19(4), 1–9.
Souza, G. N., Porto, M. de J., Santos, J. P. dos, Freitas, A. L., & Carvalho, P. P. (2021). Perfil das prescrições de antimicrobianos de uso restrito em uma Unidade de Terapia Intensiva. Research, Society and Development, 10(8), e15710816565. https://doi.org/10.33448/rsd-v10i8.16565
Wagner, J. L., Rhodes, N. J., Scheetz, M. H., Bosso, J. A., Goff, D. A., Rybak, M. J., & Davis, S. L. (2020). Opportunities for antimicrobial stewardship among carbapenem-treated patients in 18 North American hospitals. International Journal of Antimicrobial Agents, 55(6), 105970. https://doi.org/10.1016/j.ijantimicag.2020.105970
White, B. P., Patel, S., Tsui, J., & Chastain, D. B. (2019). Adding double carbapenem therapy to the armamentarium against carbapenem-resistant Enterobacteriaceae bloodstream infections. Infectious Diseases, 51(3), 161–167. https://doi.org/10.1080/23744235.2018.1527470
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Heloysa Aurélio Silva; Rafael Santos Santana; Helaine Carneiro Capucho; Ana Paula Paz de Lima; Clarisse Lisboa de Aquino Rocha; Rodrigo Fonseca Lima
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
